EUVIMEDEUVIMED entdecken
Crossref

L26/P-411 Serum progesterone concentration in women undergoing progestin-primed ovarian stimulation for fertility preservation before oncological treatments

S. Comana, N. Serra, M. Molgora, A. Lovisolo, E. Somigliana, F. Filippi

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.745 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von S. Comana und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Could an increase in serum progesterone during progestin-primed ovarian stimulation (PPOS) be detrimental in women undergoing fertility preservation for hormone-sensitive cancers? Summary answer Progesterone levels during PPOS with 200 mg daily oral micronized progesterone remained within physiological post-ovulatory ranges (20–25 ng/mL), suggesting that exposure is clinically unremarkable. What is known already According to ESHRE guidelines, random start GnRH antagonist protocols are the recommended approach for ovarian stimulation in oncologic patients undergoing fertility preservation. In elective oocyte cryopreservation, PPOS protocols are considered an equivalent alternative, being safe, less costly, associated with improved patient compliance and potentially requiring fewer monitoring visits. However, their use in oncologic patients remains debated, as progesterone levels may increase significantly in the absence of defined safety thresholds for hormone-sensitive tumors such as breast cancer. In fertile women, physiological post-ovulatory progesterone levels may reach 20–25 ng/mL. Study design, size, duration This was a prospective observational study evaluating progesterone levels in patients with cancer undergoing progestin-primed ovarian stimulation with 200 mg of daily oral micronized progesterone. The study took place between May and December 2025 at the Infertility Unit of Fondazione IRCCS Ca’ Granda Ospedale Policlinico, Milan. Participants/materials, setting, methods Patients with cancer scheduled for fertility preservation were invited to participate to this prospective observational study. Those accepting were asked to provide a serum sample for progesterone assessment during stimulation and on the day of oocyte retrieval. The study took place at a tertiary referral center between May and December 2025. Data is reported as median [interquartile range]. Main results and the role of chance Forty-three women with a median age of 31 years [26–36] and a diagnosis of cancer were recruited. Breast cancer was the most common indication (n = 21). All patients underwent random-start progestin-primed ovarian stimulation: 19 initiated stimulation in early follicular phase or amenorrhea, 10 in late follicular phase, and 14 in luteal phase. Median stimulation duration was 12 days [11–14], with a median total gonadotropin dose of 2300 IU [2012.5–2800]. The median number of cryopreserved oocytes was 8 [6.5–14]. Letrozole was co-administered in 30 patients. Serum progesterone after a median of 8 days [7–9] of stimulation was 5.9 ng/mL [4.5–13.6]. On the day of oocyte retrieval, progesterone concentration was 17 ng/mL [11.9–22.2]. Higher progesterone levels were observed in patients retrieving ≥10 oocytes compared with <10 oocytes (18.1 [13.5–24.2] vs 15.6 [7.9–20.3], p < 0.05), while remaining within the physiological post-ovulatory range. In all cases, progesterone concentrations did not exceed levels typically observed after ovulation in fertile women (approximately 20–25 ng/mL). Limitations, reasons for caution Study limitations include variability in the timing of progesterone sampling due to random-start stimulation and patient-based monitoring schedules. In addition, no established progesterone safety thresholds exist for hormone-sensitive tumors; therefore, causal inferences regarding oncologic safety cannot be drawn. Wider implications of the findings Progestin-primed ovarian stimulation with micronized progesterone may represent a valid alternative for fertility preservation also in women with hormone sensitive cancers. The absence of supraphysiological progesterone exposure, together with lower costs, fewer injections, and reduced monitoring, may be particularly relevant for patients undergoing complex oncologic care. Trial registration number No

Zitieren

APA

Comana, S., Serra, N., Molgora, M., Lovisolo, A., Somigliana, E., & Filippi, F. (2026). L26/P-411 Serum progesterone concentration in women undergoing progestin-primed ovarian stimulation for fertility preservation before oncological treatments. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.745

Vancouver

Comana S, Serra N, Molgora M, Lovisolo A, Somigliana E, Filippi F. L26/P-411 Serum progesterone concentration in women undergoing progestin-primed ovarian stimulation for fertility preservation before oncological treatments. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.745

BibTeX
@article{Comana2026,
  author = {Comana, S. and Serra, N. and Molgora, M. and Lovisolo, A. and Somigliana, E. and Filippi, F.},
  title = {L26/P-411 Serum progesterone concentration in women undergoing progestin-primed ovarian stimulation for fertility preservation before oncological treatments},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.745}
}
Kostenlos starten →